Cargando…
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare disease with a relatively short overall survival (OS). Metalloproteinases (MMPs) have a vast biological effect on tumor progression, invasion, metastasis formation, and apoptosis. MMP expression was previously associated with survival in MPM...
Autores principales: | Štrbac, Danijela, Goričar, Katja, Dolžan, Vita, Kovač, Viljem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613362/ https://www.ncbi.nlm.nih.gov/pubmed/29138529 http://dx.doi.org/10.1155/2017/8069529 |
Ejemplares similares
-
Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
por: Strbac, Danijela, et al.
Publicado: (2018) -
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019) -
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014) -
Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021) -
Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review
por: Štrbac, Danijela, et al.
Publicado: (2021)